# BioMAdvanced Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biomadvanced-diagnostics

- Industry: Healthcare
- Headquarters: Nantes, France
- Website: www.biomadvanced-diagnostics.com
- Total disclosed funding: $0.1M
- Latest round: Series A (Sep 26, 2023)
- Investors on record: 3

## About

Based in Nantes, France, and founded in 2021 by Frédéric Pette, Nicolas Bouler, Sophie Brouard, Richard Danger, and Jean-Michel Bouler, BioMAdvanced Diagnostics operates as a healthcare company that provides doctors with diagnostic aid tools in the context of personalized, predictive, and preventive medicine. In July 2023, BiomAdvanced Diagnostics raised EUR 1.4 million in venture funding from Bpifrance, Pays de la Loire Développement, and Sodero Gestion.

BioMAdvanced Diagnostics is a developer of clinical diagnostics and biomarker tests used to monitor patients' immune systems. Furthermore, the company provides tests developed by the company provides diagnostic results, and identifies biomarkers to evaluate and diagnose the risk of transplant rejection, allowing clinicians to adapt to changing and modify their patients' treatment.

The company plans to use the July 2023 funding to fuel its product development.

## Funding rounds

- Series A, Sep 26, 2023, $0.1M — Bpifrance, Sodero Gestion, Pays de la Loire Développement

## Investors

- Bpifrance — Series A
- Sodero Gestion (https://capitalatlas.ai/funds/sodero-gestion) — Series A
- Pays de la Loire Développement — Series A